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detected by COMET decreased from a steady state of 48 to 
16 mmHg along with the decrease in low and velocity. We 
conclude that COMET is ready for clinical application and 
we see the future for this bedside monitor on the intensive 
care, operating theater, and testing of mitochondrial efect 
of pharmaceuticals.
Keywords PpIX-TSLT · COMET · Mitochondrial oxygen 
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1 Introduction
Because of the importance of adequate tissue oxygen sup-
ply, many techniques have been developed for measuring 
oxygen in  vivo over the last decades [1, 2]. The ultimate 
goal of measuring oxygen at the level of the mitochondria 
has recently become reality. We introduced the protopor-
phyrin IX-triplet state lifetime technique (PpIX-TSLT) for 
measuring mitochondrial oxygen tension (mitoPO2) in 
2006 [3]. In the mean time, the technique has been proven 
to be useful in isolated cells, isolated organs and in vivo in 
animal studies [4–7].
PpIX-TSLT is based on the principle of oxygen-depend-
ent quenching of the excited triplet state of protoporphyrin 
IX (PpIX). Application of the porphyrin precursor 5-ami-
nolevulinic acid (ALA) induces PpIX in the mitochondria 
where it acts as a mitochondrial located oxygen-sensitive 
dye. After photo-excitation with a pulse of green light 
PpIX emits delayed luorescence of which the lifetime is 
inversely related to the amount of oxygen. The technique is 
non-invasive and can be safely used in humans [8].
The ability to measure optically intracellular oxy-
gen is providing the possibility to assess oxygenation at 
the end of the oxygen cascade [3, 9]. Measurements in 
Abstract After introduction of the protoporphyrin IX-
triplet state lifetime technique as a new method to meas-
ure mitochondrial oxygen tension in  vivo, the develop-
ment of a clinical monitor was started. This monitor is the 
“COMET”, an acronym for Cellular Oxygen METabolism. 
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the mitochondria. PpIX acts as a mitochondrially located 
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able in the touchscreen-integrated user interface, ‘Single’, 
‘Interval’ and ‘Dynamic measurement’. COMET is cur-
rently used in several clinical studies in our institution. In 
this irst description of the COMET device we show an 
incidental inding during neurosurgery. To treat persist-
ing intraoperative hypertension a patient was administered 
clonidine, but due to rapid administration an initial phase 
of peripheral vasoconstriction occurred. Microvascular 
low and velocity parameters measured with laser-doppler 
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the intracellular compartment are complementary to for 
example hemoglobin-based oxygen measurements. Pulse-
oximetry typically measures at the arteriolar side of the 
microcirculation [10] while near-infrared and visible light 
spectroscopy are biased toward the venous compartment 
[11, 12]. Interstitial oxygen measurements with e.g. oxygen 
electrodes measure close to the cellular compartment, but 
are cumbersome and tissue destructive [1]. Measuring at 
the end of the oxygen cascade is important since (patho-
logic) shunting in the microcirculation or the development 
of tissue edema can cause cellular hypoxia, which is other-
wise not detectable [13].
Besides measuring mitoPO2 PpIX-TSLT also provides 
the possibility to get insight in local tissue oxygen con-
sumption at the mitochondrial level [14]. Mitochondrial 
oxygen consumption (mitoVO2) can be estimated by meas-
uring the oxygen disappearance rate (ODR) in the measur-
ing volume [15]. Recently we have demonstrated that this 
enables bedside non-invasive monitoring of an important 
aspect of mitochondrial function in animal models of criti-
cal illness [16, 17].
A clinical device featuring PpIX-TSLT has now been 
developed and recently entered use in clinical trials in our 
institution. This monitor is called “COMET”, an acronym 
for Cellular Oxygen METabolism. The COMET measur-
ing system enables physicians to measure oxygen tension 
and oxygen consumption at the subcellular level in the 
mitochondria. This paper is the irst description of this CE-
marked device (Photonics Healthcare, Utrecht, The Nether-
lands). It provides the technical background, the construc-
tion of the device, and its use together with two examples 
of measurements in human skin.
2  Methods
2.1  Background of PpIX-TSLT
Protoporphyrin IX (PpIX) is the inal precursor of heme in 
the heme biosynthetic pathway and is synthesized inside 
the mitochondria [13]. The conversion of PpIX to heme in 
the mitochondria is a rate-limiting step. Therefore, admin-
istration of the porphyrin precursor 5-aminolevulinic acid 
(ALA) enhances the mitochondrial PpIX concentration 
[18]. Administration of ALA does not only enhance PpIX 
to detectable levels, but it also ensures mitochondrial origin 
of the delayed luorescence signal [3, 6, 7].
Delayed luorescence can be observed after pulsed exci-
tation of PpIX as delayed luminescence with the same 
spectrum as prompt luorescence (red light). In contrast to 
prompt luorescence delayed luorescence has a lifetime 
of tens to hundreds of microseconds [3]. Delayed luores-
cence is the result of photon emission due to spontaneous 
relaxation of the excited triplet state via bi-directional inter-
system crossing. Oxygen is a very efective quencher of the 
excited triplet state. In the process of quenching, energy is 
transferred to oxygen and PpIX relaxes to the ground state 
without emission of a photon. This causes the lifetime of 
the triplet state, and thus the lifetime of the emitted delayed 
luorescence, to be oxygen-dependent.
The delayed luorescence lifetime is inversely propor-
tional to the amount of oxygen according to the Stern–Vol-
mer Equation [8, 19]. With the assumption of a homoge-
nous distribution of oxygen this relationship can be used to 
calculate the mitochondrial oxygen tension:
where τ is the measured delayed luorescence lifetime, τ0 is 
the delayed luorescence lifetime in the absence of oxygen 
(i.e. the lifetime of spontaneous relaxation), and kq is the 
quenching constant.
2.2  Signal analysis
Oxygen however is heterogeneously distributed in tissues 
in vivo. Previous studies have shown that this also applies 
for mitoPO2 [6, 7, 13]. Delayed luorescence from a het-
erogeneous system does not decay mono-exponentially, but 
the signal contains a lifetime distribution. Fitting Eq. 1 to 
a distribution of lifetimes generally leads to an underesti-
mation of the mean PO2 in the measuring volume [20]. A 
much better estimation of the mean PO2 can be found by 
alternatively itting a distribution of quencher concentration 
to the delayed luorescence signal. The itting function for 
a simple rectangular distribution with a mean mitoPO2 Qm 
and a mitoPO2 range from Qm−δ till Qm+δ is [21]:
where YR(t) is the normalized delayed luorescence data, 
<mitoPO2> is the mean mitoPO2 within the sample vol-
ume and t is the factor time.
Fitting of Eq. 2 is fast and very robust when applied to 
weak delayed luorescence signals and noisy real world 
signals. In a previous analysis we have shown that itting 
Eq. 2 allows for reliable retrieval of mitoPO2 values from 
data with signal-to-noise ratios (SNR) as low as 10 [5]. For 
time-domain delayed luminescence measurements SNR 
is deined as the maximum amplitude of the delayed luo-
rescence divided by the maximum amplitude of the noise. 
Generally a SNR above 20 is well achievable and the noise-
induced error in the measurement remains below 2%.
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For analysis of the delayed luorescence signals COMET 
uses Eq.  2 to calculate mean mitoPO2 in the measuring 
volume under the probe. The absolute value for mitoPO2 
is directly displayed on the screen without further process-
ing. COMET also evaluates the signal quality, which is 
calculated from the SNR value; an increase of one in SNR 
is approximately 1% in signal quality up till a SNR of 50. 
Beyond a SNR 50 the increase in signal quality percentage 
will latten out. As long as SNR is within an acceptable 
range, a SNR greater than ive, COMET will show a per-
centage and a calculated mitoPO2. If COMET cannot detect 
a signal, or SNR is too low, less than or equal to ive, the 
used version of the irmware makes COMET to display “no 
signal found” and to provide the unrealistic value of “999”.
2.3  Monitor description
The COMET is a medical device and class IIa classi-
ied according to the Medical Device Directive 93/42/
EEC. The legal manufacturer is Photonics Healthcare 
B.V., Utrecht, The Netherlands. It weighs 10 kg and sizes 
22 × 33 × 29 cm without cradle and port cover on the side. 
The COMET measurement system exists of two compo-
nents shown in Fig. 1. The irst component is the monitor 
which includes the multi-touch screen integrated user inter-
face, light source, detection system and processing units. 
The second component is the COMET Skin Sensor devel-
oped for use on the human skin.
2.3.1  Hardware
The COMET is an electrically powered system (rated 
power consumption of 250  W). The light source and the 
detection system are the two core components. A 515 nm 
pulsed laser, pulse duration 60  ns, with a 10  Hz repeti-
tion rate illuminates the intra cellular accumulated PpIX. 
The luorescent signal is projected on a gated red-sensitive 
photomultiplier tube. Users can interact via a multi-touch 
12″ TFT-LCD screen. Apart from the main switch to turn 
on the device, the COMET has no physical buttons. If a 
USB storage device is inserted in the USB-port on the rear 
panel the data is exported in a comma separated ile for-
mat for further processing in programs like MS Excel. The 
COMET can be used on a lat surface or be mounted on a 
trolley or arm through a VESA 75/100 compatible adapter 
plate.
2.3.2  Software
Lifetimes of the raw data are calculated on an embedded 
control board. The embedded calculation software is writ-
ten in C code to simplify the development process as per 
IEC 62304 as required for certiication. The user interface 
(UI) is running on a separate Linux based operating system 
to enhance device usability experience.
There are three diferent types of measurement to distin-
guish, shown in Table 1.
2.4  Location of the measurement
The COMET measures oxygen tension in mitochondria by 
measuring the triplet-state lifetime of PpIX. Under nor-
mal (non-sensitized) conditions PpIX is present in very 
low concentrations in the human skin and not detectable 
with the COMET. This can be overcome by the exogenous 
administration of ALA that leads to higher concentrations 
of PpIX in the mitochondria.
ALA synthase is the irst and the rate-limiting enzyme 
of the porphyrin synthetic pathway. Under normal con-
ditions the level of heme synthesis and the intracellular 
concentration of PpIX are mainly regulated by heme 
control of the ALA synthase activity. As a small mol-
ecule, ALA penetrates the stratum corneum [22]. Exog-
enously provided ALA bypasses the negative feedback 
Fig. 1  COMET monitor and skin sensor
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controls in the heme biosynthetic pathway and leads to 
overproduction of PpIX [23].
The COMET can measure in healthy skin as well as 
in skin lesions. After ALA application the measurement 
area needs to be covered, to avoid consumption of PpIX 
by light. A priming time for ALA, typically 4 h or more, 
is needed to synthesize a suitable concentration of PpIX 
to enable measurements of mitoPO2 and oxygen disap-
pearance rate.
After topical administration on healthy skin, PpIX is 
synthesized in the epidermis but not (signiicantly) in 
the dermis [24]. While ALA penetrates into the dermis 
the heme-synthesis pathway in most dermis cells is inac-
tive. The conversion of ALA to PpIX requires energy 
and an intact heme cycle, thus PpIX is not synthesized in 
the metabolically inactive cells of the stratum corneum. 
In healthy skin this limits the intradermal measurement 
location and signal origin of the COMET to the epider-
mis with a thickness of about 0.1 mm [25].
The recommended measurement location is the skin 
of the sternum seen in Fig.  2. This provides a central 
measurement location less inluenced by temperature 
changes, movement and peripheral vasoconstriction 
[26].
2.5  Skin sensor
The biocompatible housing (70 × 20 × 20 mm) of the Skin 
Sensor, shown in Fig. 3, holds two optical ibers; the excita-
tion and the detection iber. A lexible metal tube protects 
the vulnerable optical ibers against external mechanical 
forces. The optical design of the sensor can collect light at 
approximately a right angle to the sensor cable. The light 
emitted by the sensor is divergent and safe for eyesight at 
any distance.
Ambient light entering the detection path might overload 
or even damage the photomultiplier tube. For protection, a 
photodiode in the Skin Sensor determines the ambient light 
before each measurement. Sensor temperature, used as an 
approximation of skin temperature, is measured with an 
electrical resistive sensor.
2.6  Oxygen-consumption measurement
The COMET provides the opportunity for measurements in 
dynamic situations by taking a series of 120 samples of the 
mitoPO2 acquired at 1 Hz. This can be used to determine 
the oxygen disappearance rate (ODR) and reperfusion. 
Typically, mitochondrial oxygen availability is measured 
for 10–20 s in an undisturbed and stable situation. Subse-
quently light pressure is applied with a hand onto the sen-
sor, to give occlusion of the microcirculation and stop local 
blood low in the measurement volume, for about 45  s. 
After these 45 s the pressure is released and restoration of 
microcirculatory blood low and mitochondrial re-oxygena-
tion will appear.
Table 1  The COMET diferent measurement types
Single measurement One measurement per activation of the touchscreen non physical button
Interval measurement The COMET will measure in a set interval: at the start of the interval a measurement is 
done, and the interval time can be chosen (60, 20, 5, 1 min)
Dynamic measurement The COMET can conduct a series of up to 120 measurements, one measurement per second
Fig. 2  COMET skin sensor position on the sternum
Fig. 3  Detailed view of skin sensor
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Previously, we have described the fundamental princi-
ples behind the technology and have provided a working 
implementation of the technique for mitoVO2 measure-
ments in  vivo [14]. In summary, the ODR is generally 
dependent on two factors; oxygen consumption (VO2(t)) 
and Difusive Oxygen Inlux into the measurement vol-
ume (DOI(t)). The method to calculate ODR from the 
mitoPO2 kinetics is:
The VO2(t) is oxygen-dependent and, according to 
Michaelis–Menten kinetics, can be described as:
where Vmax is the not supply-dependent maximal tissue 
oxygen consumption and P50 is the PO2 at which cellular 
oxygen consumption is reduced to 1/2 Vmax. PO2(t) denotes 
the PO2 in the measurement volume at time point t.
2.7  In human measurements
Using COMET a dynamic measurement was performed 
on a healthy volunteer. Preceding the measurements an 
ALA plaster 4  cm2 (2  mg 5-amino-4oxopentacid/cm2) 
was applied for approximately 10 h (overnight) onto the 
skin of the sternum. A baseline of 20  s was measured 
before the microcirculation was occluded. The microcir-
culation occlusion was accomplished by application of 
external pressure by hand on the Skin Sensor.
Secondly, we report an incidental inding we made 
during an ongoing feasibility study of the COMET. The 
study is performed in accordance with the declaration 
of Helsinki and patients are consented with a protocol 
approved by local ethics committee METC (CCMO 
number NL51937.078.15). This study is set up to deter-
mine the applicability, stability, and reproducibility of 
the COMET measurement over a longer period of time 
during neurosurgery. The shown incidental inding is an 
observation that occurred during non-protocolled admin-
istration of the central alpha-receptor agonist clonidine.
MitoPO2 was measured intraoperatively, simulta-
neously to tissue oxygenation saturation and perfu-
sion parameters (O2C, oxygen to see version 2424, Lea 
Medizintechnik GmbH, Germany). The O2C measures 
three parameters: The local capillary venous saturation 
(SO2), the local velocity of blood given in velocity units 
(VU) and the local micro vascular blood low given in 
low units (FU). Both the COMET Skin Sensor and the 
O2C probe (LFX-43) were positioned on the sternum 
next to each other.
ODR = dPO
2
∕dt = −VO
2
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3  Results
3.1  Oxygen-consumption measurement
A typical example of an oxygen-consumption meas-
urement on the healthy volunteer is shown in Fig.  4. 
Mean mitoPO2 (t0−19) gave a baseline mitoPO2 of 
22.7 ± 2.1  mmHg (mean ± SD). After 20  s direct pres-
sure with the probe was given to occlude microvascular 
blood low in the skin. The available oxygen was con-
sumed and resulted in an oxygen disappearance rate of 
6.3 mmHg s−1. When the pressure was released and direct 
oxygen recovery up to 60–70  mmHg in mitoPO2 was 
seen. At 120 s the mitoPO2 returned to baseline values.
3.2  Incidental inding during ongoing clinical study
In one of the measured patients during an ongoing feasi-
bility study in neurosurgery patients, clonidine was given 
intravenously due to persistent hypertension. Clonidine 
is a central inhibitor of noradrenergic neurotransmitter 
transmission but also a peripheral α1-agonist. Given in a 
short period of time clonidine leads to initial peripheral 
vasoconstriction, followed by a slow onset of vasodilata-
tion. In this particular case 150 µg of clonidine was given 
as a bolus application. A direct onset efect of vasocon-
striction on low and velocity but not on capillary venous 
oxygen saturation (SO2) was seen as measured by O2C 
Fig.  5. Flow decreased by 44% and velocity by 16%. 
Although SO2 did not change, a transient drop in mitoPO2 
was measured with the COMET. MitoPO2 dropped from 
a steady state of 48 to 16 mmHg. After the fast clonidine 
administration the restoration of blood low and velocity, 
mitoPO2 returned to baseline in approximately 15 min.
Fig. 4  A typical dynamic measurement of mitochondrial partial oxy-
gen pressure (mitoPO2) by COMET measurement system. A sample 
of 120 s is shown. In the irst 20 s the baseline was determined, after-
wards light pressure was applied on the sensor to stop microcircula-
tion and the oxygen disappearance rate (ODR) was measured. At 60 s 
pressure was released
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4  Discussion
The COMET measurement system is the successor of the 
irst clinical prototype previously described in this journal 
[17]. This new clinical monitor is safe to be used, easy to 
transport and applicable for in vivo measurement of mito-
chondrial oxygen tension and consumption in the human 
skin. The sternal skin is an easy accessible and non-inva-
sive measurement location. The clinical signiicance of 
measuring in the skin arises from the fact that, like the gut, 
the skin can be regarded as a canary of the body [27]. The 
idea is that cutaneous mitochondrial PO2 changes foretell 
changes in other vital organs and systemic parameters. 
Indeed, in an animal model mitoPO2 appeared an earlier 
indicator of approaching the limit of physiological com-
pensation during hemodilution than e.g. venous satura-
tion and lactate [27, 28]. The “canary” function of human 
skin in relation to organ function still needs further inves-
tigation but important is that also changes in cutaneous 
mitochondrial oxygen consumption correlate with ODR 
changes in other organs and tissues [17]. The ODR from 
the dynamic measurement 6.3 mmHg  s−1 in this example 
corresponds with previous data from healthy volunteers 
5.8 ± 2.3 mmHg s−1 [29] .
In this paper we describe the case of clonidine given 
to a patient within a short period of time. This incidental 
inding occurred during an ongoing neurosurgery feasibil-
ity study. This patient group was chosen because in gen-
eral we aim at hemodynamic stability during surgery over 
a longer time period. Therefore the incidental inding of an 
abrupt drop in cutaneous mitoPO2 after a bolus clonidine 
came clearly forward. In line with clinical observations the 
efects of clonidine administration resulted in initial vaso-
constriction and subsequent vasodilatation after a couple 
of minutes. Using online monitoring we observed a direct 
decline in microvascular blood low and velocity, followed 
by an increase in low and velocity as measured by the 
O2C. With the change of low and velocity a decrease in 
the oxygen supply to the tissue is expected. In consequence 
a decrease in mitoPO2 of 30 mmHg is observed as meas-
ured by the COMET.
However, interestingly, the capillary-venous oxygen sat-
uration measured by the O2C did not show any decrease 
in the minutes following clonidine administration. Two 
main phenomena could explain the unchanged capillary-
venous oxygen saturation. First, the SO2 is measured with 
the absorbance of visible light; the velocity and low are 
measured with the hemoglobin laser doppler frequency 
shift. The diferent wavelengths of light, giving a diferent 
tissue penetration and therefore measurement compartment 
[30, 31], used in these techniques may explain why a dif-
ference in low but not of SO2 after clonidine administra-
tion could be observed. A second explanation could be a 
total stop low of some capillaries. The part of the capillary 
tree without low does not contribute to venous-capillary 
saturation. Thus, the oxygen extraction in the measurement 
volume stays the same. For the COMET measurements het-
erogeneity of the oxygen content in the measurement vol-
ume could be demonstrated [8]. Therefore a heterogeneous 
bimodal distribution could explain the decrease in low and 
a constant oxygen capillary venous saturation. The reader 
should keep in mind that for practical reasons the O2C and 
COMET measurements were performed in close proximity 
of each other, but not in exactly the same area of the skin. 
However, we do think that for a valid comparison of the 
measurements the fact that SO2 and mitoPO2 were meas-
ured at the same depth in skin is of more importance. Based 
on our indings it is clear that measuring oxygen availabil-
ity directly at cellular level provides complementary data 
and new insight.
While COMET is the irst clinical device for measur-
ing mitochondrial oxygen and oxygen consumption, the 
used technology has some limitations. Currently the typi-
cal application time of the ALA on the skin is 4 h. This 
makes the measurement technique not yet applicable in 
acute situations. Furthermore, the combination of topical 
ALA administration and the green excitation light cause 
a very shallow measurement depth. While this does ena-
ble the oxygen consumption measurements, the oxygen 
Fig. 5  a Flow in arbitrary low units (FU) and arbitrary velocity in 
velocity units (VU) of microcirculation as measured with probe 2 
(P2S) O2C. b Capillary venous saturation (SO2)** as measured by 
O2C and mitochondrial partial oxygen pressure (mitoPO2) as meas-
ured by the COMET
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measurements become more sensitive to tissue heteroge-
neity and background light.
Till now the feasibility of measuring mitoPO2 and 
mitoVO2 with PpIX-TSLT was tested in healthy volun-
teers [29] and is currently further evaluated with COMET 
in the perioperative setting. However, the original main 
development idea of COMET was the in vivo determina-
tion of aspects of mitochondrial (dys)function in critical 
illness. Indeed, in the laboratory setting the efectiveness 
of this technique in determining mitochondrial function 
under septic circumstances could be demonstrated [16].
Furthermore, mitochondrial oxygen measurements 
could potentially provide a new physiological transfusion 
trigger for decision-making in transfusion medicine. In 
a very recent animal study we have shown that mitoPO2 
can be used as an early detector of reaching the indi-
vidual limit of hemodilution before changes in systemic 
oxygen consumption and lactate levels occur [27]. If this 
concept can be translated into the anemic human situa-
tion, it is indeed potentially an individual physiological 
parameter to guide blood transfusions. The technique 
used in COMET is not limited to measurements in skin, 
since ALA can be administered systemically [32, 33]. 
Therefore, endoscopic or intraoperative measurement of 
mitoPO2 is technically feasible but such attempts should 
always take into account extensive safety considerations 
related to potential photodynamic toxicity.
5  Conclusion
This report provides a description of the novel COMET 
measurement system. The enhanced protoporphyrin IX 
concentration in the skin is used as endogenous oxygen-
sensitive probe. The method gives the possibility to meas-
ure cellular oxygen availability and the oxygen disappear-
ance rate at the bedside on a mitochondrial level. In the 
future the COMET could play a role in clinical practice 
to assess tissue viability, to manage oxygen transport, and 
to recognize and possibly to treat mitochondrial inhibi-
tion in critically ill patients. Furthermore it potentially 
can be used as an individual blood transfusion trigger and 
may enable testing mitochondrial efects of pharmaceuti-
cal substances research.
Acknowledgements The COMET has been developed with support 
of Eurostars project E!7294 in close cooperation between the Depart-
ment of Anesthesiology at the Erasmus Medical Center in Rotterdam 
and the company Photonics Healthcare in Utrecht. We thank Dr. Her-
bert Stepp and Dr. Dominic Robinson for their advice.
Compliance with ethical standards 
Conlict of interest Dr. E.G. Mik and F. Michael Münker are found-
ers and shareholders of Photonics Healthcare, a company aimed at 
making the delayed luorescence lifetime technology available to a 
broad public. Photonics Healthcare B.V. holds the exclusive licenses 
to several patents regarding this technology, iled and owned by the 
Academic Medical Center in Amsterdam and the Erasmus Medical 
Center in Rotterdam, The Netherlands.
Open Access This article is distributed under the terms of the 
Creative Commons Attribution 4.0 International License (http://
creativecommons.org/licenses/by/4.0/), which permits unrestricted 
use, distribution, and reproduction in any medium, provided you give 
appropriate credit to the original author(s) and the source, provide a 
link to the Creative Commons license, and indicate if changes were 
made.
References
 1. Springett R, Swartz HM. Measurements of oxygen in vivo: over-
view and perspectives on methods to measure oxygen within 
cells and tissues. Antioxid Redox Signal. 2007;9:1295–301.
 2. Swartz HM, Dunn JF. Measurements of oxygen in tissues: 
overview and perspectives on methods. Adv Exp Med Biol. 
2003;530:1–12.
 3. Mik EG, Stap J, Sinaasappel M, et al. Mitochondrial PO2 meas-
ured by delayed luorescence of endogenous protoporphyrin IX. 
Nat Methods. 2006;3:939–45.
 4. Balestra GM, Mik EG, Eerbeek O, et al. Increased in vivo mito-
chondrial oxygenation with right ventricular failure induced by 
pulmonary arterial hypertension: mitochondrial inhibition as 
driver of cardiac failure? Respir Res. 2015;16:6.
 5. Bodmer SIA, Balestra GM, Harms FA, et  al. Microvascu-
lar and mitochondrial PO(2) simultaneously measured by 
oxygen-dependent delayed luminescence. J Biophotonics. 
2012;5:140–51.
 6. Mik EG, Ince C, Eerbeek O, et al. Mitochondrial oxygen tension 
within the heart. J Mol Cell Cardiol. 2009;46:943–51.
 7. Mik EG, Johannes T, Zuurbier CJ, et  al. In vivo mitochondrial 
oxygen tension measured by a delayed luorescence lifetime 
technique. Biophys J. 2008;95:3977–90.
 8. Mik EG. Special article: measuring mitochondrial oxygen ten-
sion: from basic principles to application in humans. Anesth 
Analg. 2013;117:834–46.
 9. Treacher DF, Leach RM. Oxygen transport-1. Basic principles. 
BMJ. 1998;317:1302–6.
 10. Alexander CM, Teller LE, Gross JB. Principles of pulse oxi-
metry: theoretical and practical considerations. Anesth Analg. 
1989;68:368–76.
 11. Franceschini MA, Boas DA, Zourabian A, et  al. Near-infrared 
spiroximetry: noninvasive measurements of venous saturation in 
piglets and human subjects. J Appl Physiol. 2002;92:372–84.
 12. Benaron DA, Parachikov IH, Friedland S, et al. Continuous, non-
invasive, and localized microvascular tissue oximetry using vis-
ible light spectroscopy. Anesthesiology. 2004;100:1469–75.
 13. Ince C, Mik EG. Microcirculatory and mitochondrial 
hypoxia in sepsis, shock, and resuscitation. J Appl Physiol. 
2016;120:226–35.
 14. Harms FA, Voorbeijtel WJ, Bodmer SIA, et  al. Cutaneous 
respirometry by dynamic measurement of mitochondrial oxygen 
tension for monitoring mitochondrial function in  vivo. Mito-
chondrion. 2013;13:507–14.
 J Clin Monit Comput
1 3
 15. Harms FA, Mik EG. In vivo assessment of mitochondrial oxygen 
consumption. Methods Mol Biol. 2015;1264:219–29.
 16. Harms FA, Bodmer SIA, Raat NJH, Mik EG. Non-invasive mon-
itoring of mitochondrial oxygenation and respiration in critical 
illness using a novel technique. Crit Care. 2015;19:343.
 17. Harms FA, Bodmer SIA, Raat NJH, Mik EG. Cutaneous mito-
chondrial respirometry: non-invasive monitoring of mitochon-
drial function. J Clin Monit Comput. 2015;29:509–19.
 18. Fukuda H, Casas A, Batlle A. Aminolevulinic acid: from its 
unique biological function to its star role in photodynamic ther-
apy. Int J Biochem Cell Biol. 2005;37:272–6.
 19. Mik EG, Donkersloot C, Raat NJH, Ince C. Excitation pulse 
deconvolution in luminescence lifetime analysis for oxygen 
measurements in vivo. Photochem Photobiol. 2002;76:12–21.
 20. Johannes T. Dual-wavelength phosphorimetry for determination 
of cortical and subcortical microvascular oxygenation in rat kid-
ney. J Appl Physiol. 2005;100:1301–10.
 21. Golub AS, Popel AS, Zheng L, Pittman RN. Analysis of phos-
phorescence in heterogeneous systems using distributions of 
quencher concentration. Biophys J. 1997;73:452–65.
 22. Kennedy JC, Pottier RH. Endogenous protoporphyrin IX, a clini-
cally useful photosensitizer for photodynamic therapy. J Photo-
chem Photobiol B. 1992;14:275–92.
 23. Malik Z, Kostenich G, Roitman L, et al. Topical application of 
5-aminolevulinic acid, DMSO and EDTA: protoporphyrin IX 
accumulation in skin and tumours of mice. J Photochem Photo-
biol B. 1995;28:213–8.
 24. Gof BA, Bachor R, Kollias N, Hasan T. Efects of photody-
namic therapy with topical application of 5-aminolevulinic acid 
on normal skin of hairless guinea pigs. J Photochem Photobiol B. 
1992;15:239–51.
 25. Sandby-Møller J, Poulsen T, Wulf HC. Epidermal thickness 
at diferent body sites: relationship to age, gender, pigmenta-
tion, blood content, skin type and smoking habits. Acta Derm 
Venereol. 2003;83:410–3.
 26. Campbell I. Body temperature and its regulation. Anaesth. Inten-
sive Care Med. 2008;9:259–63.
 27. Römers LHL, Bakker C, Dollée N, et  al. Cutaneous mitochon-
drial PO2, but not tissue oxygen saturation, is an early indicator 
of the physiologic limit of hemodilution in the pig. Anesthesiol-
ogy. 2016;125:124–32.
 28. O’Brien EO, Schmidt U. Cellular hypoxia in a brand new light. 
Anesthesiology. 2016;125:20–1.
 29. Harms F, Stolker RJ, Mik E. Cutaneous respirometry as novel 
technique to monitor mitochondrial function: a feasibility study 
in healthy volunteers. PLoS ONE. 2016;11:163399.
 30. Meglinsky IV, Matcher SJ. Modelling the sampling volume for 
skin blood oxygenation measurements. Med Biol Eng Comput. 
2001;39:44–50.
 31. Vongsavan N, Matthews B. Some aspects of the use of laser 
Doppler low meters for recording tissue blood low. Exp Phys-
iol. 1993;78:1–14.
 32. Guyotat J, Pallud J, Armoiry X, et  al. 5-Aminolevulinic acid-
protoporphyrin IX luorescence-guided surgery of high-grade 
gliomas: a systematic review. Adv Tech Stand Neurosurg. 2016. 
doi:10.1007/978-3-319-21359-0_3.
 33. Namikawa T, Yatabe T, Inoue K, et al. Clinical applications of 
5-aminolevulinic acid-mediated luorescence for gastric cancer. 
World J Gastroenterol. 2015;21:8769–75.
